This is the authors' abstract. We don't add key points for this paper.
Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Klampfl et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: